{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:07:27Z","timestamp":1777486047118,"version":"3.51.4"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"crossref","award":["IG17009"],"award-info":[{"award-number":["IG17009"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.cytogfr.2017.05.003","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T03:00:26Z","timestamp":1494990026000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma"],"prefix":"10.1016","volume":"36","author":[{"given":"Luigi","family":"Fattore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cytogfr.2017.05.003_bib0005","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"October (10)","key":"10.1016\/j.cytogfr.2017.05.003_bib0010","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1016\/j.bbadis.2014.03.011","article-title":"Genetic variation in the non-coding genome: involvement of micro-RNAs and long non-coding RNAs in disease","volume":"1842","author":"Hrdlickova","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"July (10)","key":"10.1016\/j.cytogfr.2017.05.003_bib0015","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.7150\/thno.11543","article-title":"MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer","volume":"5","author":"Bertoli","year":"2015","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.cytogfr.2017.05.003_bib0020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.cytogfr.2017.05.003_bib0025","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","article-title":"MicroRNAs in cancer: biomarkers, functions and therapy","volume":"20","author":"Hayes","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbior.2014.09.013","article-title":"MicroRNA and cancer\u2014a brief overview","volume":"57","author":"Acunzo","year":"2014","journal-title":"Adv. Biol. Regul."},{"issue":"November (10)","key":"10.1016\/j.cytogfr.2017.05.003_bib0035","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/blood-2008-03-147645","article-title":"MYC stimulates EZH2 expression by repression of its negative regulator miR-26a","volume":"112","author":"Sander","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cytogfr.2017.05.003_bib0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1261\/rna.041814.113","article-title":"Biogenesis of intronic miRNAs located in clusters by independent transcription and alternative splicing","volume":"20","author":"Ramalingam","year":"2014","journal-title":"RNA"},{"issue":"24","key":"10.1016\/j.cytogfr.2017.05.003_bib0045","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.cytogfr.2017.05.003_bib0050","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/978-3-319-22539-5_10","article-title":"Targeted therapy for melanoma","volume":"167","author":"Wong","year":"2016","journal-title":"Cancer Treat. Res."},{"issue":"February (4)","key":"10.1016\/j.cytogfr.2017.05.003_bib0060","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"August (9)","key":"10.1016\/j.cytogfr.2017.05.003_bib0065","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S1470-2045(14)70072-5","article-title":"Systemic treatment for BRAF-mutant melanoma: where do we go next?","volume":"15","author":"Menzies","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0075","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF","volume":"7287","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0085","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/pgs.11.166","article-title":"Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas","volume":"2","author":"Lo","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"21","key":"10.1016\/j.cytogfr.2017.05.003_bib0095","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.18632\/oncotarget.2602","article-title":"Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma","volume":"5","author":"Spagnolo","year":"2014","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.cytogfr.2017.05.003_bib0100","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2017.05.003_bib0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.cytogfr.2017.05.003_bib0110","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(15)00087-X","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.cytogfr.2017.05.003_bib0115","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1158\/1078-0432.CCR-15-1762","article-title":"Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies","volume":"22","author":"Krepler","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.cytogfr.2017.05.003_bib0120","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.cytogfr.2017.05.003_bib0130","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/pcmr.12264","article-title":"Adaptive resistance to RAF inhibitors in melanoma","volume":"27","author":"Kugel","year":"2014","journal-title":"Pigment. Cell Melanoma Res."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1479-5876-11-180","article-title":"Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF\/MEK inhibition and is abrogated by anti-ErbB3 antibodies","volume":"11","author":"Fattore","year":"2013","journal-title":"J. Transl. Med."},{"issue":"28","key":"10.1016\/j.cytogfr.2017.05.003_bib0140","doi-asserted-by":"crossref","first-page":"24823","DOI":"10.18632\/oncotarget.4485","article-title":"Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF\/MEK inhibitors in melanoma","volume":"6","author":"Fattore","year":"2015","journal-title":"Oncotarget"},{"issue":"34","key":"10.1016\/j.cytogfr.2017.05.003_bib0145","doi-asserted-by":"crossref","first-page":"E5005","DOI":"10.1073\/pnas.1607753113","article-title":"miR-579-3p controls melanoma progression and resistance to target therapy","volume":"113","author":"Fattore","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"January","key":"10.1016\/j.cytogfr.2017.05.003_bib0150","article-title":"MicroRNAs in melanoma development and resistance to target therapy","author":"Fattore","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.cytogfr.2017.05.003_bib0155","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/jid.2008.452","article-title":"miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma","volume":"129","author":"Mueller","year":"2009","journal-title":"J. Invest. Dermatol."},{"issue":"8","key":"10.1016\/j.cytogfr.2017.05.003_bib0160","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/jid.2010.63","article-title":"MicroRNA expression profiles associated with mutational status and survival in malignant melanoma","volume":"130","author":"Caramuta","year":"2010","journal-title":"J. Invest. Dermatol."},{"issue":"11","key":"10.1016\/j.cytogfr.2017.05.003_bib0165","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.4161\/cc.10.11.15777","article-title":"MicroRNA signatures differentiate melanoma subtypes","volume":"10","author":"Chan","year":"2011","journal-title":"Cell Cycle"},{"issue":"7","key":"10.1016\/j.cytogfr.2017.05.003_bib0170","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/jid.2011.451","article-title":"Histology-specific microRNA alterations in melanoma","volume":"132","author":"Poliseno","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"7","key":"10.1016\/j.cytogfr.2017.05.003_bib0175","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.18632\/oncotarget.2923","article-title":"MicroRNA dysregulation in uveal melanoma: a new player enters the game","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.cytogfr.2017.05.003_bib0180","doi-asserted-by":"crossref","first-page":"e72699","DOI":"10.1371\/journal.pone.0072699","article-title":"In-depth characterization of microRNA transcriptome in melanoma","volume":"8","author":"Kozubek","year":"2013","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.cytogfr.2017.05.003_bib0185","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/onc.2012.209","article-title":"Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions","volume":"32","author":"Couts","year":"2012","journal-title":"Oncogene"},{"issue":"May (3)","key":"10.1016\/j.cytogfr.2017.05.003_bib0190","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/pcmr.12343","article-title":"MicroRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis","volume":"28","author":"Tembe","year":"2015","journal-title":"Pigment. Cell Melanoma Res."},{"issue":"52","key":"10.1016\/j.cytogfr.2017.05.003_bib0195","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1038\/onc.2008.282","article-title":"Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma","volume":"27","author":"M\u00fcller","year":"2008","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.cytogfr.2017.05.003_bib0200","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1158\/0008-5472.CAN-15-2932","article-title":"miR-339-3p is a tumor suppressor in melanoma","volume":"76","author":"Weber","year":"2016","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cytogfr.2017.05.003_bib0205","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1158\/1541-7786.MCR-15-0425-T","article-title":"miR-146a exerts differential effects on melanoma growth and metastatization","volume":"14","author":"Raimo","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2017.05.003_bib0210","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.18632\/oncotarget.3070","article-title":"miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy","volume":"6","author":"Bhattacharya","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cytogfr.2017.05.003_bib0215","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12967-016-0811-2","article-title":"Exosome-mediated transfer of miR-222 is sufficient to increase tumor malignancy in melanoma","volume":"14","author":"Felicetti","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.abb.2014.07.012","article-title":"MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma","volume":"563","author":"Strong","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"issue":"19","key":"10.1016\/j.cytogfr.2017.05.003_bib0225","doi-asserted-by":"crossref","first-page":"9444","DOI":"10.18632\/oncotarget.2452","article-title":"miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2","volume":"5","author":"Liu","year":"2014","journal-title":"Oncotarget"},{"issue":"Part 3","key":"10.1016\/j.cytogfr.2017.05.003_bib0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1467-9868.00346","article-title":"A direct approach to false discovery rates","volume":"64","author":"Storey","year":"2002","journal-title":"J. R. Stat. Soc. B"},{"issue":"February (4)","key":"10.1016\/j.cytogfr.2017.05.003_bib0235","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/emboj.2010.358","article-title":"Targeting Notch signalling by the conserved miR-8\/200 microRNA family in development and cancer cells","volume":"30","author":"Vallejo","year":"2011","journal-title":"EMBO J."},{"issue":"May (5)","key":"10.1016\/j.cytogfr.2017.05.003_bib0240","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"March (6)","key":"10.1016\/j.cytogfr.2017.05.003_bib0245","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ijc.25461","article-title":"Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer","volume":"128","author":"Wiklund","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"August (8)","key":"10.1016\/j.cytogfr.2017.05.003_bib0250","doi-asserted-by":"crossref","first-page":"e105570","DOI":"10.1371\/journal.pone.0105570","article-title":"miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"February (7)","key":"10.1016\/j.cytogfr.2017.05.003_bib0255","doi-asserted-by":"crossref","first-page":"8223","DOI":"10.18632\/oncotarget.6972","article-title":"microRNA-203 suppresses invasion and epithelial-mesenchymal transition induction via targeting NUAK1 in head and neck cancer","volume":"7","author":"Obayashi","year":"2016","journal-title":"Oncotarget"},{"issue":"August (8)","key":"10.1016\/j.cytogfr.2017.05.003_bib0260","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nmeth.3485","article-title":"miRWalk2.0: a comprehensive atlas of microRNA-target interactions","volume":"12","author":"Dweep","year":"2015","journal-title":"Nat. Methods"},{"issue":"May (9)","key":"10.1016\/j.cytogfr.2017.05.003_bib0265","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1158\/0008-5472.CAN-07-5867","article-title":"Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development","volume":"68","author":"Cheung","year":"2008","journal-title":"Cancer Res."},{"issue":"June (11)","key":"10.1016\/j.cytogfr.2017.05.003_bib0270","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1158\/0008-5472.CAN-14-2156","article-title":"Rho kinase inhibitors block melanoma cell migration and inhibit metastasis","volume":"75","author":"Sadok","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2017.05.003_bib0275","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang da","year":"2009","journal-title":"Nat. Protoc."},{"issue":"January (1)","key":"10.1016\/j.cytogfr.2017.05.003_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nar\/gkn923","article-title":"Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists","volume":"37","author":"Huang da","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"February (2)","key":"10.1016\/j.cytogfr.2017.05.003_bib0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/cdd.2012.137","article-title":"MIRUMIR: an online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets","volume":"20","author":"Antonov","year":"2013","journal-title":"Cell Death Differ."},{"issue":"19","key":"10.1016\/j.cytogfr.2017.05.003_bib0290","doi-asserted-by":"crossref","first-page":"17753","DOI":"10.18632\/oncotarget.3924","article-title":"miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma","volume":"6","author":"Stark","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.cytogfr.2017.05.003_bib0295","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-13-2625","article-title":"Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence","volume":"74","author":"Nissan","year":"2014","journal-title":"Cancer Res."},{"issue":"January","key":"10.1016\/j.cytogfr.2017.05.003_bib0300","article-title":"Upregulation of microRNA-1246 is associated with BRAF inhibitor resistance in melanoma cells with mutant BRAF","author":"Kim","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0305","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/pcmr.12578","article-title":"MicroRNA -125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway","volume":"30","author":"Koetz-Ploch","year":"2017","journal-title":"Pigment. Cell Melanoma Res."},{"issue":"April (2)","key":"10.1016\/j.cytogfr.2017.05.003_bib0310","first-page":"255","article-title":"Cytokines in cancer drug resistance: cues to new therapeutic strategies","volume":"1865","author":"Jones","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"January (3)","key":"10.1016\/j.cytogfr.2017.05.003_bib0315","article-title":"MicroRNA targeting to modulate tumor microenvironment","volume":"6","author":"Kuninty","year":"2016","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cytogfr.2017.05.003_bib0320","doi-asserted-by":"crossref","first-page":"e684","DOI":"10.1038\/cddis.2013.213","article-title":"Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression","volume":"4","author":"Bullock","year":"2013","journal-title":"Cell Death Dis."},{"issue":"April (8)","key":"10.1016\/j.cytogfr.2017.05.003_bib0325","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1002\/ijc.25506","article-title":"Micro-RNA-21 regulates TGF-\u03b2-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction","volume":"128","author":"Yao","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2017.05.003_bib0330","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/cdd.2015.78","article-title":"Stromal miR-200\u2009s contribute to breast cancer cell invasion through CAF activation and ECM remodeling","volume":"23","author":"Tang","year":"2015","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.cytogfr.2017.05.003_bib0335","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.18632\/oncotarget.6599","article-title":"Overcoming melanoma resistance to vemurafenib by targeting CCL2- induced miR-34a, miR-100 and miR-125b","volume":"7","author":"Vergani","year":"2016","journal-title":"Oncotarget"},{"issue":"August (33)","key":"10.1016\/j.cytogfr.2017.05.003_bib0340","doi-asserted-by":"crossref","first-page":"53558","DOI":"10.18632\/oncotarget.10669","article-title":"miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR\/IGF-1R\/CRAF and inhibiting the MAPK and PI3K\/AKT signaling pathways","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.cytogfr.2017.05.003_bib0345","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.ajpath.2012.07.009","article-title":"miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1","volume":"181","author":"Liu","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.cytogfr.2017.05.003_bib0350","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/pcmr.12379","article-title":"miR-200c\/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment","volume":"28","author":"Liu","year":"2015","journal-title":"Pigment. Cell Melanoma Res."},{"issue":"October (5)","key":"10.1016\/j.cytogfr.2017.05.003_bib0355","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/ncomms6241","article-title":"Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression","volume":"28","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.cytogfr.2017.05.003_bib0360","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1158\/0008-5472.CAN-13-3279","article-title":"Identification of a tumor-suppressive human-specific microRNA within the FHIT tumor-suppressor gene","volume":"74","author":"Hu","year":"2014","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2017.05.003_bib0365","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ccr.2013.03.013","article-title":"Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1\/CDK1-phosphorylated nuclear iASPP","volume":"23","author":"Lu","year":"2013","journal-title":"Cancer Cell"},{"issue":"March (3)","key":"10.1016\/j.cytogfr.2017.05.003_bib0370","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/jid.2012.357","article-title":"miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes","volume":"133","author":"Luo","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"August","key":"10.1016\/j.cytogfr.2017.05.003_bib0375","article-title":"Predicting effective microRNA target sites in mammalian mRNAs","volume":"4","author":"Agarwal","year":"2015","journal-title":"Elife"},{"issue":"March (1)","key":"10.1016\/j.cytogfr.2017.05.003_bib0380","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961011730059X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961011730059X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T12:41:31Z","timestamp":1667652091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135961011730059X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":76,"alternative-id":["S135961011730059X"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2017.05.003","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2017.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}